Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients

T cell receptor (TCR) T cell therapies target tumor antigens in a human leukocyte antigen (HLA)-restricted manner. Biomarker-defined therapies require validation of assays suitable for determination of patient eligibility. For clinical trials evaluating TCR T cell therapies targeting melanoma-associ...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Tianjiao Wang, Jean-Marc Navenot, Stavros Rafail, Cynthia Kurtis, Mark Carroll, Marian Van Kerckhoven, Sofie Van Rossom, Kelly Schats, Konstantinos Avraam, Robyn Broad, Karen Howe, Ashley Liddle, Amber Clayton, Ruoxi Wang, Laura Quinn, Joseph P. Sanderson, Cheryl McAlpine, Carly Carozza, Eric Pimpinella, Susan Hsu, Francine Brophy, Erica Elefant, Paige Bayer, Dennis Williams, Marcus O. Butler, Jeffrey M. Clarke, Justin F. Gainor, Ramaswamy Govindan, Victor Moreno, Melissa Johnson, Janet Tu, David S. Hong, George R. Blumenschein, Jr.
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2024-06-01
Schriftenreihe:	Molecular Therapy: Methods & Clinical Development
Schlagworte:	HLA immunotherapy MAGE-A4 T cell receptor T cell therapy biomarker
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2329050124000810
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!